122 related articles for article (PubMed ID: 38290205)
1. Serum cell division control 42 reflects treatment response and survival profiles in recurrent or metastatic oral squamous cell carcinoma patients who receive programmed death-1 inhibitors.
Chen Y; Chen Y; Liu W
Int Immunopharmacol; 2024 Mar; 129():111547. PubMed ID: 38290205
[TBL] [Abstract][Full Text] [Related]
2. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
3. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Okamoto I; Sato H; Tsukahara K
Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
[TBL] [Abstract][Full Text] [Related]
4. Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes.
Xu J; Shao R; Zhang X; Yao D; Han S
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102149. PubMed ID: 37247692
[TBL] [Abstract][Full Text] [Related]
5. Serum Cell Division Cycle 42 before and after Programmed Death-1 Inhibitor Therapy in Advanced Melanoma Patients: Correlation with Tumor Features, Clinical Response, and Survival.
Zhang L; Zhang S; Han Z; Liu Z; Xu Y; Li X; Miao G; Niu L
Tohoku J Exp Med; 2024 Mar; 262(2):133-141. PubMed ID: 37914283
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
[TBL] [Abstract][Full Text] [Related]
7. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
8. Serum cell division cycle 42 reflects the treatment response and survival in patients with advanced cervical cancer who receive immune checkpoint inhibitor treatment.
Guo L; Su Y; Liu X; Xie W; Meng S; Liu Y; Wang W; Lv X; Wang C
Oncol Lett; 2023 Sep; 26(3):414. PubMed ID: 37600330
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
12. Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yin G; Guo W; Duan H; Huang Z
Clin Otolaryngol; 2021 Sep; 46(5):1013-1020. PubMed ID: 33765363
[TBL] [Abstract][Full Text] [Related]
13. Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients.
Jiang L; Shen Y; Wang Y
Scand J Clin Lab Invest; 2023 Apr; 83(2):103-110. PubMed ID: 36811410
[TBL] [Abstract][Full Text] [Related]
14. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
[TBL] [Abstract][Full Text] [Related]
15. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
Dang S; Zhang S; Zhao J; Li X; Li W
Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
[TBL] [Abstract][Full Text] [Related]
17. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
18. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
[TBL] [Abstract][Full Text] [Related]
19. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]